JP7343924B2 - ポリペプチド - Google Patents
ポリペプチド Download PDFInfo
- Publication number
- JP7343924B2 JP7343924B2 JP2021554929A JP2021554929A JP7343924B2 JP 7343924 B2 JP7343924 B2 JP 7343924B2 JP 2021554929 A JP2021554929 A JP 2021554929A JP 2021554929 A JP2021554929 A JP 2021554929A JP 7343924 B2 JP7343924 B2 JP 7343924B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- block
- polypeptide
- cells
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 92
- 229920001184 polypeptide Polymers 0.000 title claims description 78
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 78
- 150000001413 amino acids Chemical class 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 54
- 210000002889 endothelial cell Anatomy 0.000 claims description 34
- 230000021164 cell adhesion Effects 0.000 claims description 31
- 210000004204 blood vessel Anatomy 0.000 claims description 22
- 238000001338 self-assembly Methods 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 18
- 239000002473 artificial blood Substances 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 239000002131 composite material Substances 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 52
- 229940024606 amino acid Drugs 0.000 description 52
- 238000012360 testing method Methods 0.000 description 28
- 239000011248 coating agent Substances 0.000 description 22
- 238000000576 coating method Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 101100015566 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GPG1 gene Proteins 0.000 description 11
- 239000011521 glass Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- -1 isoleucine Amino acids Chemical class 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000012620 biological material Substances 0.000 description 5
- 239000002121 nanofiber Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 206010002329 Aneurysm Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012758 nuclear staining Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000008823 permeabilization Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 210000001644 umbilical artery Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 2
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 2
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101100540159 Candida albicans (strain SC5314 / ATCC MYA-2876) TFP1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100316793 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VMA1 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本発明は、その一態様において、(配列番号1:X1GGX2G)nからなるG配列ブロックと(配列番号2:VPGX3G)mからなるP配列ブロックを含むエラスチン様ブロックペプチド配列、及び末端に配置された内皮細胞接着配列を含む、ポリペプチド(本明細書において、「本発明のポリペプチド」と示すこともある。)に関する。以下に、これについて説明する。
本発明は、その一態様において、本発明のポリペプチドのコード配列を含む、ポリヌクレオチド(本明細書において、「本発明のポリヌクレオチド」と示すこともある。)に関する。以下、これについて説明する。
本発明は、その一態様において、
・本発明のポリペプチドの繊維状自己集合体(本発明の繊維状自己集合体)、
・本発明の自己集合体を含む、成型体(本発明の成型体)、
・本発明の繊維状自己集合体及び本発明の成型体からなる群より選択される少なくとも1種と、基材とを含む、複合材料(本発明の複合材料)、
・本発明の繊維状自己集合体、本発明の成型体、及び本発明の複合材料からなる群より選択される少なくとも1種を含む、医療機器、生体材料、実験器具等
に関する。以下に、これらについて説明する。
下記3つのポリペプチド(GPG1、GPG3、及びGPG-REDV):
(GPG1)N末端側から(配列番号5:VGGVG)5からなるG配列ブロック、(配列番号6:VPGXG)25からなるP配列ブロック(式中、Xは同一又は異なってV又はFを示す。)、(配列番号5:VGGVG)5からなるG配列ブロックの順に、各ブロックがリンカー配列を介在して連結してなるエラスチン様ブロックペプチド配列を含むポリペプチド(配列番号7)、
(GPG3)GPG1のC末端側に細胞接着配列が配置されてなるポリペプチド(配列番号8)、及び
(GPG-REDV)GPG1のC末端側に内皮細胞接着配列が配置されてなるポリペプチド(配列番号9)、
を合成した。GPG1及びGPG3は既報のアミノ酸配列からなるポリペプチドであり、GPG-REDVは今般新たに設計したポリペプチドである。
GPG-REDVを20μMの濃度で冷水に溶解後、37℃で7日間静置し、自己集合性ナノファイバーを得た。ナノファイバーは透明分散液として得られた。ナノファイバーの形成は、原子間力顕微鏡観察により確認した。
ポリペプチド(GPG1、GPG3、及びGPG-REDV)をファイバー形成させた場合と、ファイバー未形成(単分子状)の場合とで、基板へのコーティング率を測定した。具体的には以下のようにして行った。
GPG1、GPG3、及びGPG-REDVとコラーゲンとで、コーティング率を比較した。GPG1、GPG3、及びGPG-REDVについては、ファイバー形成サンプルを使用し、サンプルを組織培養用プレート上に滴下した後の静置時間を2時間とする以外は、試験例3と同様にして行った。また、コラーゲンについても、ファイバー形成用静置処理(37℃7日間)を行わない以外は、GPG1、GPG3、及びGPG-REDVと同様にして行った。
試験例4で得られた各コーティングプレート(1wellの面積:0.3cm2)に、HUVEC細胞(ヒト臍帯静脈内皮細胞)を1.0×104cells/wellになるように播種し、37℃で1時間又は24時間培養した。培養後、細胞を4%パラホルムアルデヒドで固定(4℃、30分間)し、続いて0.5%TritonX-100で透過処理(4℃、25分間)し、続いて1%BSAでブロッキング処理(25℃、1時間)した。一次抗体(抗ビンキュリン抗体及び抗アクチン抗体)溶液で処理(4℃、12時間)し、続いて二次抗体処理(抗ビンキュリン抗体に対する蛍光標識抗体溶液で25℃で1時間処理後に、抗アクチン抗体に対する蛍光標識抗体溶液で4℃で30分間処理)し、続いて核染色処理(25℃、5分間)を行った。細胞を、蛍光顕微鏡で観察し、核の数を計測して、得られた値を元に、プレートの単位面積当たりの細胞数を算出した。さらに、観察像から、プレート面積に対する細胞の占有面積の割合を算出した。
試験例4で得られた各コーティングプレート(1wellの面積:0.3cm2)に、HUVEC細胞(ヒト臍帯静脈内皮細胞)を1.0×103cells/wellになるように播種し、37℃で1、3、5、又は7日間培養した。培養後、細胞を4%パラホルムアルデヒドで固定(4℃、30分間)し、続いて0.5%TritonX-100で透過処理(4℃、25分間)し、続いて1%BSAでブロッキング処理(25℃、1時間)した。一次抗体(抗フォン・ヴィレブランド因子抗体及び抗アクチン抗体)溶液で処理(4℃、12時間)し、続いて二次抗体処理(抗フォン・ヴィレブランド因子抗体に対する蛍光標識抗体溶液で25℃で1時間処理後に、抗アクチン抗体に対する蛍光標識抗体溶液で4℃で30分間処理)し、続いて核染色処理(25℃、5分間)を行った。細胞を、蛍光顕微鏡で観察し、核の数を計測して、得られた値を元に、プレートの単位面積当たりの細胞数を算出した。
全血を200gで5分間遠心して上清を回収した。上清を1500gで10分間遠心して、沈殿(血小板)を細胞培養培地に懸濁して、血小板懸濁液を得た。試験例4で得られた各コーティングプレート(1wellの面積:0.9cm2)に、血小板懸濁液を3.5×106cells/wellになるように播種し、37℃で1時間静置した。血小板をPBSで洗浄後、血小板を1%グルタルアルデヒドで固定(37℃、2時間)した。血小板をPBSで洗浄し、続いて50%PBS(超純水希釈)で洗浄し、続いて超純水で洗浄した。血小板を、電界放出型走査電子顕微鏡(FE-SEM)で観察し、プレートの単位面積当たりの各形態(Type1:偽足0本、Type2:偽足1-2本、Type3:偽足3本以上)の血小板数を算出した。
平滑筋細胞には、収縮型と合成型が存在する。収縮型は、正常な血管に存在し、紡錘形である、収縮性を有する、アルファ平滑筋アクチン(αSMA)の発現する等の特徴を有する。一方、合成型は、病理状態の血管に存在し、丸い形状を有する、細胞外マトリックスの合成が活発である、高い増殖性と遊走能を有する等の特徴を有する。人工血管材料は、平滑筋細胞が問題なく培養でき、且つ平滑筋細胞の合成型への分化を誘導しないことが求められる。平滑筋細胞が活性化(合成型へ分化)してしまうと、血管が肥厚する(開存性が保たれない)原因となる。そこで、血管平滑筋細胞の接着性、増殖性等を評価した。具体的には、以下のようにして行った。
試験例4で得られた各コーティングプレート(1wellの面積:0.3cm2)に、HUASMC細胞(ヒト臍帯動脈平滑筋細胞)を1.0×104cells/wellになるように播種し、37℃で24時間培養した。培養後、細胞を4%パラホルムアルデヒドで固定(4℃、30分間)し、続いて0.5%TritonX-100で透過処理(4℃、25分間)し、続いて1%BSAでブロッキング処理(25℃、1時間)した。一次抗体(抗ビンキュリン抗体及び抗アクチン抗体)溶液で処理(4℃、12時間)し、続いて二次抗体処理(抗ビンキュリン抗体に対する蛍光標識抗体溶液で25℃で1時間処理後に、抗アクチン抗体に対する蛍光標識抗体溶液で4℃で30分間処理)し、続いて核染色処理(25℃、5分間)を行った。細胞を、蛍光顕微鏡で観察し、核の数を計測して、得られた値を元に、プレートの単位面積当たりの細胞数を算出した。さらに、観察像から、プレート面積に対する細胞の占有面積の割合を算出した。
試験例4で得られた各コーティングプレート(1wellの面積:0.3cm2)に、HUASMC細胞(ヒト臍帯動脈平滑筋細胞)を2.0×103cells/wellになるように播種し、37℃で1、3、5、又は7日間培養した。培養後、細胞を4%パラホルムアルデヒドで固定(4℃、30分間)し、続いて0.5%TritonX-100で透過処理(4℃、25分間)し、続いて1%BSAでブロッキング処理(25℃、1時間)した。一次抗体(抗平滑筋抗体(αSMA)及び抗アクチン抗体)溶液で処理(4℃、12時間)し、続いて二次抗体処理(抗平滑筋抗体に対する蛍光標識抗体溶液で25℃で1時間処理後に、抗アクチン抗体に対する蛍光標識抗体溶液で4℃で30分間処理)し、続いて核染色処理(25℃、5分間)を行った。細胞を、蛍光顕微鏡で観察し、核の数を計測して、得られた値を元に、プレートの単位面積当たりの細胞数を算出した。
試験例4で得られた各コーティングプレート(1wellの面積:0.3cm2)に、HUASMC細胞(ヒト臍帯動脈平滑筋細胞)を2.0×103cells/wellになるように播種し、37℃で7日間培養した。CellAmpTM Direct Lysis and RT set(タカラバイオ社製)を用い、推奨プロトコルに従ってセルライセート作製と逆転写反応を行った。続いて、インターカレーター法を用いたリアルタイムポリメラーゼ連鎖反応(rt-PCR)によりαSMA (ACTA2) の遺伝子発現量を測定した。ハウスキーピング遺伝子としてグリセルアルデヒドー3-リン酸脱水素酵素(GAPDH)を用いた。Primerの配列を下表に示す。TB GreenTM Premix Ex TaqTMII(タカラバイオ社製)12.5 μL、forward primer (10 μmol/L)およびreverse primer(10 μmol/L) 各1μL、上記で調製済の逆転写反応液 2.5 μL、滅菌精製水 8 μL を氷上で混合してPCR反応液を調製した。この反応液から Thermal Cycler Dice Real Time System III(タカラバイオ社製)を用いて標準プロトコルに従いPCR反応を行った。増幅曲線と閾値線の交点(Ct値)をCrossing Point法で求め、ΔΔCt法でACTA2発現量を算出した。使用したプライマー(配列番号11~14)を表3に示す。
試験例8-1の結果を図5に示す。平滑筋細胞は、GPG-REDVに、細胞培養用ガラス基板よりも有意に多く接着した。細胞占有率は、GPG-REDVとガラス基板で同程度であった。
Claims (12)
- (配列番号1:X1GGX2G)nからなるG配列ブロック(式中、X1は同一又は異なってV又はLを示し、X2は同一又は異なってV又はLを示し、nは4以上の整数を示す。)と(配列番号2:VPGX3G)mからなるP配列ブロック(式中、X3は同一又は異なって任意のアミノ酸を示し、mは5以上の整数を示す。)を含むエラスチン様ブロックペプチド配列、及び末端に配置された内皮細胞接着配列を含み、
前記内皮細胞接着配列がREDV(配列番号3)を含む、ポリペプチド。 - 前記エラスチン様ブロックペプチド配列の配列構造が、N末端側から、G配列ブロック-P配列ブロック-G配列ブロック、G配列ブロック-P配列ブロック-P配列ブロック-G配列ブロック、P配列ブロック-G配列ブロック、又はG配列ブロック-P配列ブロックである、請求項1に記載のポリペプチド。
- 前記ブロック間にリンカー配列が介在する、請求項1又は2に記載のポリペプチド。
- 前記内皮細胞接着配列がGREDV(配列番号4)である、請求項1~3のいずれかに記載のポリペプチド。
- 前記内皮細胞接着配列の末端側とは反対側に親水性アミノ酸リッチ配列が配置されている、請求項1~4のいずれかに記載のポリペプチド。
- 請求項1~5のいずれかに記載のポリペプチドのコード配列を含む、ポリヌクレオチド。
- 請求項1~5のいずれかに記載のポリペプチドの発現ベクターである、請求項6に記載のポリヌクレオチド。
- 請求項6又は7に記載のポリヌクレオチドを含む、細胞。
- 請求項1~5のいずれかに記載のポリペプチドの繊維状自己集合体。
- 請求項9に記載の繊維状自己集合体を含む、成型体。
- 請求項9に記載の繊維状自己集合体及び請求項10に記載の成型体からなる群より選択される少なくとも1種と、基材とを含む、複合材料。
- 請求項9に記載の繊維状自己集合体、請求項10に記載の成型体、及び請求項11に記載の複合材料からなる群より選択される少なくとも1種を含む、人工血管。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019200444 | 2019-11-05 | ||
JP2019200444 | 2019-11-05 | ||
PCT/JP2020/041001 WO2021090787A1 (ja) | 2019-11-05 | 2020-11-02 | ポリペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2021090787A1 JPWO2021090787A1 (ja) | 2021-05-14 |
JP7343924B2 true JP7343924B2 (ja) | 2023-09-13 |
Family
ID=75848496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021554929A Active JP7343924B2 (ja) | 2019-11-05 | 2020-11-02 | ポリペプチド |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7343924B2 (ja) |
WO (1) | WO2021090787A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023195332A1 (ja) * | 2022-04-07 | 2023-10-12 | 国立大学法人東海国立大学機構 | 細胞培養又は増殖基材 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516519A (ja) | 1999-04-28 | 2003-05-13 | アイトゲノシッシュ テヒニッシュ ホーホシューレ チューリッヒ | 分析用デバイスおよびセンシングデバイスにおけるポリイオン性コーティング |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330911A (en) * | 1989-09-28 | 1994-07-19 | Board Of Regents, The University Of Texas System | Surfaces having desirable cell adhesive effects |
-
2020
- 2020-11-02 JP JP2021554929A patent/JP7343924B2/ja active Active
- 2020-11-02 WO PCT/JP2020/041001 patent/WO2021090787A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516519A (ja) | 1999-04-28 | 2003-05-13 | アイトゲノシッシュ テヒニッシュ ホーホシューレ チューリッヒ | 分析用デバイスおよびセンシングデバイスにおけるポリイオン性コーティング |
Non-Patent Citations (2)
Title |
---|
DEVALLIERE, Julie et al.,Improving functional re-endothelialization of acellular liver scaffold using REDV cell-binding domain,Acta Biomaterialia,2018年,Volume 78,151-164 |
LE, Duc H. T. et al.,Double-hydrophobic elastin-like polypeptides with added functional motifs: Self-assembly and cytocompatibility, Journal of Biomedical Materials Research. Part A,2017年,Volume 105, Issue 9,2475-2484 |
Also Published As
Publication number | Publication date |
---|---|
WO2021090787A1 (ja) | 2021-05-14 |
JPWO2021090787A1 (ja) | 2021-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11279743B2 (en) | Cell-permeable bone morphogenetic protein (CPBMP) recombinant protein and use thereof | |
CA2340328C (en) | Stable hypoxia inducible factor-1 alpha and method of use | |
Subramanian et al. | Shortstop recruits EB1/APC1 and promotes microtubule assembly at the muscle-tendon junction | |
US20120171770A1 (en) | Bioengineered silk protein-based nucleic acid delivery systems | |
US9931437B2 (en) | Matrix scaffold with antimicrobial activity | |
US10851152B2 (en) | Polymerized peptide and gel having collagen-like structure | |
US20090325866A1 (en) | Non-activated wnt inhibition polypeptides and method for preparing the same | |
TW201207111A (en) | Cell penetrating peptides for intracellular delivery | |
WO2012149515A2 (en) | Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use | |
KR100912741B1 (ko) | 모듈식 트랜스펙션 시스템 | |
ES2960784T3 (es) | Variantes del péptido ATF5 y usos de las mismas | |
WO2020171161A1 (ja) | 自己組織化ペプチド | |
JP7343924B2 (ja) | ポリペプチド | |
Malcor et al. | Coupling of a specific photoreactive triple-helical peptide to crosslinked collagen films restores binding and activation of DDR2 and VWF | |
CA2438334C (en) | Ocular tear growth factor-like protein | |
DK2575846T3 (en) | Insulin-like growth factor-1 receptor binding peptides | |
US20050147602A1 (en) | Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix | |
JP2006508675A (ja) | 調節性ジンクフィンガータンパク質 | |
US10508265B2 (en) | Cell-permeable reprogramming factor (iCP-RF) recombinant protein and use thereof | |
EP4137505A1 (en) | Self-assembling peptide | |
WO2021187478A1 (ja) | 自己組織化ペプチドを含む組成物 | |
JPWO2007132555A1 (ja) | 細胞膜透過性ペプチドと細胞内におけるその使用 | |
JP7241358B2 (ja) | 細胞移植用組成物及び細胞移植方法 | |
WO2011046519A1 (en) | Polypeptide material composed of elastin-like segments and coiled coil segments | |
KR20090122769A (ko) | 세포내로 단백질을 전달하는 방법 및 이를 위한 펩타이드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230531 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230801 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230825 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7343924 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |